Morgan Stanley
OKUR

Morgan Stanley’s OnKure Therapeutics OKUR Stock Holding History

Morgan Stanley’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.3K Sell
14,327
-10,635
-43% -$32.8K ﹤0.01% 6356
2025
Q4 		$72.4K Buy
24,962
+7,748
+45% +$23.2K ﹤0.01% 6314
2025
Q3 		$47.3K Buy
17,214
+513
+3% +$1.27K ﹤0.01% 6420
2025
Q2 		$39.9K Buy
16,701
+14,823
+789% +$38.9K ﹤0.01% 6428
2025
Q1 		$8.08K Buy
1,878
+946
+102% +$5.32K ﹤0.01% 6866
2024
Q4 		$8.02K Sell
932
-5,520
-86% -$83.6K ﹤0.01% 6877
2024
Q3 		$110K Sell
6,452
-13,400
-67% -$198K ﹤0.01% 5972
2024
Q2 		$300K Sell
19,852
-2,864
-13% -$48.6K ﹤0.01% 5503
2024
Q1 		$377K Sell
22,716
-2,269
-9% -$37.4K ﹤0.01% 5435
2023
Q4 		$400K Buy
24,985
+21,753
+673% +$1.36M ﹤0.01% 5703
2023
Q3 		$246K Sell
3,232
-344
-10% -$23.4K ﹤0.01% 5493
2023
Q2 		$235K Sell
3,576
-657
-16% -$52.9K ﹤0.01% 5579
2023
Q1 		$253K Buy
4,233
+276
+7% +$10K ﹤0.01% 5598
2022
Q4 		$92.2K Sell
3,957
-32
-0.8% -$848 ﹤0.01% 6012
2022
Q3 		$134K Buy
3,989
+1,939
+95% +$63.7K ﹤0.01% 5928
2022
Q2 		$54K Buy
2,050
+1,509
+279% +$35.1K ﹤0.01% 6575
2022
Q1 		$16K Sell
541
-174
-24% -$9.74K ﹤0.01% 7242
2021
Q4 		$61K Buy
715
+299
+72% +$22K ﹤0.01% 6721
2021
Q3 		$30K Sell
416
-2,703
-87% -$229K ﹤0.01% 6930
2021
Q2 		$291K Buy
+3,119
New +$348K ﹤0.01% 5831

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley's OKUR Position: Q1 2026 in Review

Morgan Stanley reduced its OnKure Therapeutics (OKUR) stake by 43% in Q1 2026, selling an estimated $32.8K and leaving 14,327 shares worth $59.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6356.

Morgan Stanley first reported a position in OKUR in Q2 2021 and has held it in 20 quarters since. The position peaked at $400K in Q4 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Morgan Stanley held 14,327 shares of OnKure Therapeutics worth $59.3K as of Q1 2026.
  • Morgan Stanley sold 10,635 OnKure Therapeutics shares in Q1 2026, an estimated $32.8K.
  • OnKure Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6356 holding.
  • Morgan Stanley first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Morgan Stanley's OnKure Therapeutics position peaked at $400K in Q4 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.